Probatebeta
Target

SCN8A

Sodium channel protein type 8 subunit alpha

As of the edition of 20 October 2026, SCN8A (sodium channel protein type 8 subunit alpha, UniProt Q9UQD0) has 55 drugs tested at it and 13 companies on the list, 2 on route A and 4 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q9UQD0
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
7
Disease areas
Nervous system; Mental health; Injuries; Cancer; Bones, joints and muscles; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive
Registered trials of its drugs
2,671

Drugs at this target

StatusCount
Marketed44
Active3
Went quiet6
Stopped1
Withdrawn from market1
Total55
DrugStatusFurthest phaseUS protection
LidocaineMarketedPhase 4none listed
RopivacaineMarketedPhase 4none listed
TopiramateMarketedPhase 4none listed
LamotrigineMarketedPhase 4none listed
CarbamazepineMarketedPhase 4none listed
LacosamideMarketedPhase 4Ended 2026
RiluzoleMarketedPhase 4none listed
TetracaineMarketedPhase 4none listed
Eslicarbazepine acetateMarketedPhase 4Ended 2026
ZonisamideMarketedPhase 4none listed
PhenytoinMarketedPhase 4none listed
ArticaineMarketedPhase 4none listed

12 of 55 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A2
Route B4
Engaged7
Total on the list13
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
NeurocrineRoute A
GSKRoute B

The other 10 companies at SCN8A

In the product

13 companies in all; 10 are not named here, and no score is.

See the 13 companies at SCN8A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at SCN8A

Other targets in nervous system

Companies holding approvals at SCN8A